Pacific Biosciences/$PACB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Ticker
$PACB
Sector
Primary listing
Employees
575
Headquarters
Website
PACB Metrics
BasicAdvanced
$360M
-
-$1.83
2.17
-
Price and volume
Market cap
$360M
Beta
2.17
52-week high
$2.41
52-week low
$0.85
Average daily volume
6.5M
Financial strength
Current ratio
6.918
Quick ratio
5.807
Long term debt to equity
1,136.005
Total debt to equity
1,142.027
Interest coverage (TTM)
-63.63%
Profitability
EBITDA (TTM)
-225.738
Gross margin (TTM)
27.56%
Net profit margin (TTM)
-337.17%
Operating margin (TTM)
-398.23%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-33.28%
Return on equity (TTM)
-189.96%
Valuation
Price to revenue (TTM)
2.216
Price to book
5.86
Price to tangible book (TTM)
-1.32
Price to free cash flow (TTM)
-2.199
Free cash flow yield (TTM)
-45.48%
Free cash flow per share (TTM)
-0.546
Growth
Revenue change (TTM)
-17.35%
Earnings per share change (TTM)
21.07%
3-year revenue growth (CAGR)
3.81%
10-year revenue growth (CAGR)
6.90%
3-year earnings per share growth (CAGR)
24.52%
10-year earnings per share growth (CAGR)
8.28%
What the Analysts think about PACB
Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.
Bulls say / Bears say
The company kept its full-year revenue outlook at $155 million to $170 million, despite its cost-cutting measures, showing management's confidence in stable demand.
Preliminary Q1 revenue came in at $36.9 million, beating the consensus estimate of $33.5 million and pointing to stronger-than-expected sales momentum.
Shares jumped 8.7% after announcing expense reductions, signaling that the market is responding positively to proactive cost management.
The company will cut about 120 jobs to reduce annual operating expenses by $45–$50 million, which could hamper R&D efforts and slow down product innovation.
Even with the recent share rally, the stock is still down roughly 53% since President Trump began his term, highlighting ongoing valuation challenges.
The company remains heavily dependent on NIH reimbursements, and with these now subject to policy changes and tariff pressure, there is significant risk to revenue if federal funding declines further.
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
PACB Financial Performance
Revenues and expenses
PACB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pacific Biosciences stock?
Pacific Biosciences (PACB) has a market cap of $360M as of September 16, 2025.
What is the P/E ratio for Pacific Biosciences stock?
The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of September 16, 2025.
Does Pacific Biosciences stock pay dividends?
No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Pacific Biosciences dividend payment date?
Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.
What is the beta indicator for Pacific Biosciences?
Pacific Biosciences (PACB) has a beta rating of 2.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.